TG Therapeutics (TGTX) Misses Q4 EPS by 12c

TG Therapeutics (NASDAQ: TGTX) reported Q4 EPS of ($0.39), $0.12 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $80 thousand versus the consensus estimate of $1.83 million.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Wynn Resorts prices $900M senior notes offering at 6.875%
• RUM Group to raise Northern Data stake to ~98% via share purchase